SecBot SecBot
SECBOTREPLAY Home › Report › ALNY

ALNY · Fidelity stake 9.5%

ALNYLAM PHARMACEUTICALS, INC. · SC 13G/A filed Nov 5, 2026 at 13:10 ET

At the news

NEUTRALIMPACT 3/10

SC 13G/A filed Nov 5, 2026 at 13:10 ET

FMR LLC (Fidelity) filed an amended Schedule 13G disclosing a 9.5% passive stake in Alnylam Pharmaceuticals as of September 30, 2026, up from a prior filing. This is a routine update for a large passive holder and does not signal any change in investment intent or control.

  • FMR LLC reported beneficial ownership of 12,675,052.96 shares of Alnylam common stock as of September 30, 2026.
  • The stake represents 9.5% of the outstanding shares.
  • The filing is an amendment to Schedule 13G, certifying passive intent under Rule 13d-1(b).
  • Fidelity Management & Research Company LLC is the entity within the FMR group that beneficially owns 5% or more of the class.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access